Navigation Links
Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
Date:1/16/2008

SEATTLE, Jan. 16 /PRNewswire/ -- Hagens Berman Sobol Shapiro has begun an investigation concerning actions by Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP), manufacturers of Zetia and Vytorin. The investigation is looking into charges of whether Merck and Schering-Plough violated state consumer protection laws arising from the sale and marketing of Zetia and Vytorin.

Vytorin is the combination of Zetia and Zocor, a statin now available as a generic drug for about one-third of the cost.

The investigation centers around charges that the companies have known since 2006 that the combination of drugs was no more effective than the generic version of Zocor in blocking the fatty arterial plaques that can cause heart attack and stroke, as it led consumers to believe.

Zetia is a brand-name prescription used to lower LDL levels by decreasing cholesterol absorption in the intestinal tract. Other cholesterol-lowering drugs known as statins work in the liver.

Zetia was developed by Schering-Plough and jointly marketed by Merck and Shering-Plough, as is Vytorin.

According to published reports, the two companies promoted Zetia heavily, advertising that by adding it to statin treatment, patients could more effectively lower LDL cholesterol which they claim would, in turn, reduce plaque in patients' arteries.

But according to media reports, the companies had prior information that refuted that claim.

On January 14, 2008, Merck/Schering-Plough released the results of a drug trial intended to prove the claim and show a correlation between lowered LDL levels and fatty plaques in the arteries, which can cause heart attacks and strokes, according to published documents.

The investigation centers on allegations that while the study once again showed that Vytorin lowered LDL cholesterol rates better than Zocor alone, it also showed that the fatty arterial plaques actually grew somewhat faster in patients taking Zetia along with Zocor than in those taking Zocor alone.

The investigation is also looking into questions regarding the timing of the study's release. According to published reports, the two-year drug trial concluded April 2006 but wasn't announced until January 15, 2008. Reports also suggest Merck and Schering-Plough knew the results of the trials but delayed sharing the findings with patients and did not change its marketing approach.

Zetia and Vytorin account for combined sales of $1.1 billion during the fourth quarter of 2007. The agreement with Merck and Schering-Plough provided that the companies split profits roughly 50-50, depending on regions.

The investigation is examining remedies for patients, including the possibility of legal action seeking the return of money to purchasers of Vytorin and Zetia, which the study shows are no more effective than the generic form of Zocor.

If you are a Vytorin or Zetia patient and would like more information about the investigation, please visit http://www.hbsslaw.com/zetia.htm or e-mail info@hbsslaw.com.

About Hagens Berman Sobol Shapiro

Hagens Berman Sobol Shapiro is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix and San Francisco. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation; a $340 million recovery on behalf of Enron employees; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in a $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit http://www.hbsslaw.com.

CONTACTS:

Steve Berman (206) 623-7292

Hagens Berman Sobol Shapiro

Steve@hbsslaw.com

Mark Firmani (206) 443-9357

Firmani + Associates, Inc.

Mark@firmani.com


'/>"/>
SOURCE Hagens Berman Sobol Shapiro
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
2. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
3. Universal Health Services, Inc. Announces Dividend
4. BD Announces Webcast of Annual Meeting of Shareholders
5. STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call
6. Chem Rx Announces the Appointment of Three New Directors
7. Brighton Hospital Announces Creation of Brighton National Addiction Foundation
8. PreMD Announces FDA Decision on POC Skin Cholesterol Test
9. Virginia Cares Uninsured Program (VCUP) Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare
10. Caris Diagnostics Announces Addition of Leading Dermatopathologist to Expand Subspecialty Expertise
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Demand ... at the East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at ... more than 40 speakers — representing such thought-leading companies as JP Morgan ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... service and innovation, the company recently unveiled a redesigned website. The new site ... the work of building owners, architects, contractors and other industry users that Garland ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... variety of settings, gather for the National Athletic Trainers’ Association Annual Clinical Symposium ... case studies presented. It is also when Athletic Trainers are acknowledged by their ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey ... With Vaginas.” The goal is to ignite conversation via social media and word-of-mouth ... The brand has declared September “Humans with Vaginas” month, releasing a video celebrating ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare and ... that it will transition to using only Worksheet S-10 to distribute Disproportionate Share Hospital ... three live 60-minute complimentary webinars on October 17, 2017 at 2 P.M. ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... Pa. , Sept. 5, 2017  Xyntek Inc. has announced another milestone ... a new Midwest office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 ... ... of customer engagements regionally. ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology: